CN1943583A - Freeze-dried preparation for treating cerebral vascular disease - Google Patents
Freeze-dried preparation for treating cerebral vascular disease Download PDFInfo
- Publication number
- CN1943583A CN1943583A CN 200610051232 CN200610051232A CN1943583A CN 1943583 A CN1943583 A CN 1943583A CN 200610051232 CN200610051232 CN 200610051232 CN 200610051232 A CN200610051232 A CN 200610051232A CN 1943583 A CN1943583 A CN 1943583A
- Authority
- CN
- China
- Prior art keywords
- solution
- ginsenoside
- lyophilized formulations
- freeze
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 19
- 208000019553 vascular disease Diseases 0.000 title abstract 2
- 230000002490 cerebral effect Effects 0.000 title description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 48
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 46
- FBFMBWCLBGQEBU-GYMUUCMZSA-N 20-gluco-ginsenoside-Rf Natural products O([C@](CC/C=C(\C)/C)(C)[C@@H]1[C@H]2[C@H](O)C[C@H]3[C@](C)([C@]2(C)CC1)C[C@H](O[C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@H]1C(C)(C)[C@@H](O)CC[C@]31C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FBFMBWCLBGQEBU-GYMUUCMZSA-N 0.000 claims description 46
- HYPFYJBWSTXDAS-UHFFFAOYSA-N Ginsenoside Rd Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C4CCC5C(C)(C)C(CCC5(C)C4CC(O)C23C)OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C HYPFYJBWSTXDAS-UHFFFAOYSA-N 0.000 claims description 46
- UOJAEODBOCLNBU-UHFFFAOYSA-N vinaginsenoside R4 Natural products C1CC(C2(CC(O)C3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O UOJAEODBOCLNBU-UHFFFAOYSA-N 0.000 claims description 46
- 238000009472 formulation Methods 0.000 claims description 41
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- 238000004108 freeze drying Methods 0.000 claims description 31
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 14
- 229920002307 Dextran Polymers 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 10
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 238000000859 sublimation Methods 0.000 claims description 10
- 230000008022 sublimation Effects 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002510 pyrogen Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000005262 decarbonization Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000001954 sterilising effect Effects 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 12
- 229940089161 ginsenoside Drugs 0.000 abstract 1
- 229930182494 ginsenoside Natural products 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 239000008280 blood Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 13
- 229960000715 nimodipine Drugs 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000017531 blood circulation Effects 0.000 description 12
- 210000000269 carotid artery external Anatomy 0.000 description 11
- 208000005189 Embolism Diseases 0.000 description 9
- 208000001435 Thromboembolism Diseases 0.000 description 9
- 206010061216 Infarction Diseases 0.000 description 8
- 206010008118 cerebral infarction Diseases 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- 206010028851 Necrosis Diseases 0.000 description 7
- 239000004677 Nylon Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000017074 necrotic cell death Effects 0.000 description 7
- 229920001778 nylon Polymers 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 206010008190 Cerebrovascular accident Diseases 0.000 description 6
- 241000180649 Panax notoginseng Species 0.000 description 6
- 235000003143 Panax notoginseng Nutrition 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 244000131316 Panax pseudoginseng Species 0.000 description 3
- 210000004004 carotid artery internal Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 2
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000002551 anterior cerebral artery Anatomy 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 229940063517 omeprazole sodium Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KNVABRFVZVESIL-UHFFFAOYSA-N sodium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound [Na+].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C KNVABRFVZVESIL-UHFFFAOYSA-N 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A freeze-dried medication for treatment of cranial vascular disease is presented, prepared by taking ginsenoside as material and auxiliary material of excipient acceptable by pharmacology, mixing into solution of proper density and then through freeze-dried.
Description
Technical field
The present invention relates to a kind of lyophilized formulations for the treatment of cerebrovascular disease and preparation method thereof, is preparation of a kind of newtype drug and preparation method thereof, belongs to technical field of medicaments.
Background technology:
Contain many different components in the Chinese medicine, wherein topmost active ingredient must be arranged.Pharmacological research to effective components of Chinese medicinal, can be reasonable formula provides the theoretical foundation of science, the explanation of modern medicine viewpoint also is provided for motherland's medical science simultaneously, wherein in recent years the traditional Chinese medical science " syndrome of blood stasis " is reached the research of " blood circulation promoting and blood stasis dispelling " square medicine, obtained great achievement in this respect." syndrome of blood stasis " is " blood vessels are obstructed ", " qi and blood stagnation " and the various pathological changes that cause comprise pathological changes such as inflammation, degeneration, atrophy, necrosis.The traditional Chinese medical science adopts the treatment means of " invigorating blood circulation ", " blood stasis dispelling ", is equivalent to the microcirculation improvement of modern medicine, improves hemorheological property, improves and organizes oxygen supply, and the protection cell avoids degeneration, necrosis, finally reach remove sickly decrease, the purpose of repair tissue.
It is generally acknowledged that cerebrovascular disease such as cerebral hemorrhage, cerebral thrombosis, cerebral infarction belong to the traditional Chinese medical science " apoplexy category ".Though the etiology and pathogenesis of apoplexy is complicated, always with disturb on positive QI-insufficiency, hepatic and renal YIN deficiency, the liver-yang, liver-wind stirring up internally is for causing a disease this.Deficiency of both QI and blood, Liver and kidney imbalance of YIN and YANG cause QI-blood circulation and are obstructed, or the QI and blood superinverse, and last illiteracy is positive refreshing; Or QI and blood is contrary disorderly follows Liver Channel, flings the top, mountain peak, damage brain network, blood stasis brain key and falling ill.Control according to dialectical executing, on the rule of treatment, dispelling pathogenic wind and eliminating phlegm is arranged, promoting blood circulation to remove obstruction in the collateral, the benefiting QI and nourishing blood eliminating blood stasis and smoothing collaterals, the blood circulation promoting regulates qi disperse blood stasis and dredge collateral, the nourishing YIN for suppressing the hyperactive YANG calming wind and dredging collateral, methods such as eliminating phlegm removing dampness inducing resuscitation collateral dredging, the key of each method still is a collateral dredging.To " apoplexy " treatment of cerebral hemorrhage, cerebral thrombosis, the early stage rule of treatment should be with removing blood stasis with potent drugs collateral dredging, blood circulation promoting and blood stasis dispelling to remove the stasis of blood of brain internal organs.The back something lost mark disease treatment in later stage is also with eliminating blood stasis and smoothing collaterals phase 5.
Radix Notoginseng is the effective drug for invigorating blood circulation and eliminating stasis that is usually used in treating apoplexy, in recent years the composition of Radix Notoginseng has been carried out the research of wide model, and has isolated the dissimilar Saponin as effective ingredient.Its effective ingredient Radix Notoginseng total arasaponins, in these total Saponins, ginsenoside-rd belongs to the effective constituent that mainly contains of pseudo-ginseng blood-circulation-invigovating, has the usefulness of drug for invigorating blood circulation and eliminating stasis and is used for the treatment of apoplexy effectively.Ginsenoside-rd is the monomer that separation and Extraction is come out from Radix Ginseng total saponins, Radix Notoginseng total arasaponins, the total Saponin of gynostemma pentaphyllum, and action target spot is identical with Radix Notoginseng total arasaponins, can block being subjected to actuated Ca specifically
2+Passage; In view of the above, ginsenoside-rd has Radix Ginseng total saponins, Radix Notoginseng total arasaponins, the such blood circulation promoting and blood stasis dispelling characteristic of the total Saponin of gynostemma pentaphyllum equally, and the apoplexy card that comprises cerebrovascular disease such as cerebral hemorrhage cerebral infarction that the reply syndrome of blood stasis is relevant has therapeutic efficacy.Ginsenoside-rd not only provides the explanation of modern theory for syndrome of blood stasis and drug for invigorating blood circulation and eliminating stasis, also shown the bright prospects of Chinese medicine drug for invigorating blood circulation and eliminating stasis treatment Cerebral Ischemia damage.Ginsenoside-rd is as the effective monomer of drug for invigorating blood circulation and eliminating stasis, has good treatment Cerebral Ischemia damage and downright bad effect, is the medicine of treatment cerebrovascular disease with new class of China's Chinese medicine characteristic.
According to the definition of 2005 editions appendix IU of Chinese Pharmacopoeia to injection: injection mean medical material through extract, purification close make for injecting intravital solution of people or emulsion and for facing with the powder of preceding wiring solution-forming or the sterile preparation of concentrated solution.The advantage of injection is a bioavailability height, rapid-action, is applicable to the emergency and severe disease patient.Though injection is a kind of good dosage form,, the injection of solution or emulsion is because principal agent composition physical property has more quality problems during preparation.The injection problem of normal appearance is, produces muddy or precipitation, and solution colour is deepened or the like.When these problems occurring, can consider to adopt and select moulding process or be prepared into the powder that supplies to face with preceding wiring solution-forming.And preparation for the method for facing with the powder of preceding wiring solution-forming in, generally can adopt spray drying or lyophilization because the medicine that the present invention relates to is very responsive for temperature, high thermally labile is so select for use lyophilization to prepare.The evaluation of lyophilized formulations quality, mainly be to investigate lyophilized formulations mouldability, dissolubility, water content, and influence these indexs is to select suitable excipient as filler, if excipient select improper or only select a kind of excipient, lyophilized formulations can occur subsiding, not full, loose or hard, problem such as dissolubility is relatively poor, the present invention adopts compound excipient, certainly separated the problem that lyophilized formulations occurs easily, made lyophilized formulations be easy to production, more stable quality, medication is safer.
Summary of the invention
The injection that the objective of the invention is to solve preparation solution or emulsion becomes turbid or precipitation, solution colour are deepened, and causes the unsafe problem of drug use; Be to solve preparation lyophilized formulations excipient select improper or only use a kind of excipient, lyophilized formulations can occur subsiding, not full, loose or hard, problem such as dissolubility is relatively poor.The present invention selects compound excipient, and a kind of lyophilized formulations external form for the treatment of cerebrovascular disease of making is full, hardness suits, be easy to dissolving.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention is made after lyophilization by the solution that contains ginsenoside Rd and pharmaceutically acceptable excipient.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention, described ginsenoside Rd is a kind of or any one the above mixture that is selected from ginsenoside-rd, ginsenoside-rd hydrate or their derivant or their salt.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention, described pharmaceutically acceptable excipient are one or more the materials that is selected from mannitol, dextran, lactose, sodium chloride, glucose, Na2EDTA, glycine or other the pharmaceutically acceptable excipient; Best selection is: mannitol, dextran, Na2EDTA.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention, the pH value of solution of described ginsenoside Rd of containing and pharmaceutically acceptable excipient are 5.5～8.5.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention, described solution can also contain one or more materials in alkali compounds, buffer system and the acid of the described solution pH value of pharmaceutically acceptable scalable.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention, described solution also contains acceptable adjuvant on the conventional pharmaceutical that comprises stabilizing agent, analgesics and buffer agent and one or more material in the medicine with other miscellaneous functions is arranged.
The lyophilized formulations of the said treatment cerebrovascular disease of the present invention is made after lyophilization by the solution that contains ginsenoside Rd and excipient; The pH value of described solution is 5.5～8.5; Described solution volume ratio by weight contains ginsenoside Rd 0.01%～10%, described solution volume ratio by weight contains excipient 0.5%～40%, wherein, the proportion of composing of excipient is: mannitol: dextran: Na2EDTA is 30～65%: 55～27.5%: 15～7.5%, and the surplus of described solution is a solvent; Described solution is solvent with water and/or pharmaceutically acceptable organic solvent.
The preparation method of the lyophilized formulations of the said treatment cerebrovascular disease of the present invention comprises:
(1) preparation contains the solution of ginsenoside Rd, pharmaceutically acceptable excipient, removes impurity, pyrogen, decolouring, and the method for filtration sterilization comprises: the pH value of regulator solution is 5.5～8.5; In the described solution ginsenoside Rd's content by weight volume ratio be 0.01%～10% and excipient content by weight volume ratio be 0.5%～40%; Described pharmaceutically acceptable excipient is the mixture of mannitol, dextran, Na2EDTA, and proportion of composing is 30～65%: 55～27.5%: 15～7.5%; Described remove pyrogen be with solution by adding 0.05%～5% active carbon, preferred 0.1%～2%, under 25 ℃～60 ℃, preferred 20 ℃～30 ℃, stirred 10～30 minutes, filtering decarbonization is finished;
(2) described lyophilization may further comprise the steps:
1. pre-freeze: the temperature in the freeze drying box is reduced to-15 ℃～-25 ℃ respectively in advance, the lyophilizing solution for the treatment of that branch installs is put into freeze drying box and carried out pre-freeze 1～2 hour;
2. freezing: as the temperature in the freeze drying box to be reduced to-35 ℃～-45 ℃, continued freezing 3～5 hours;
3. sublimation drying: vacuum in the freeze drying box is risen to below the 1.5Kpa, close fridge, slowly heating per hour to heat up 3 ℃, was carried out sublimation drying 20～25 hours;
4. dry again: baking temperature is controlled at 25 ℃～35 ℃, until treating the freeze-dried products temperature near this temperature, freeze-day with constant temperature 4～6 hours, promptly.
Diseases such as the present invention is used for the treatment of that facial hemiparalysis due to the obstruction of collaterals by blood stasis, speech are unfavorable, hemiplegia, the body of the tongue stasis of blood are dim, hesitant pulse; Also can be used for treating acute cerebrovascular disease and cause cerebral tissue ischemia/reperfusion injury, necrosis, see above patient; Order of the present invention is to have solved ginsenoside-rd can not be water-soluble fully, directly uses the injection water as solvent to make the injection of solution or emulsion, the problem of solution muddiness occurs; Problems such as solved the preparation lyophilized formulations and selected improper or a kind of excipient of lyophilized formulations excipient, to subside can appear in lyophilized formulations, not full, loose or hard, and dissolubility is relatively poor; Also solved the problem of redissolving when using after the multiple lyophilizing of lyophilized formulations, the present invention adopts mannitol, dextran, Na2EDTA as compound excipient, and the pH of regulator solution is 5.5～8.5, make that the lyophilized formulations external form of making is full, hardness suits, be easy to dissolving, the ginsenoside-rd dissolving fully when the present invention was redissolved the ginsenoside-rd lyophilized formulations, solution is clear and bright, stable in properties, improved bioavailability of medicament, guaranteed the drug safety of medicine, make curative effect faster, the effect stronger.
Core of the present invention is to use compound excipient, adopt pharmaceutically acceptable excipient mannitol, dextran, the mixture of Na2EDTA, make the lyophilized formulations external form of making full, hardness is suitable, be easy to dissolving, improved the dissolubility when the ginsenoside-rd lyophilized formulations redissolves, simultaneously in order to increase the stability of ginsenoside-rd in solution, solution is also selected the alkali compounds of this solution pH value of pharmaceutically acceptable scalable, one or more materials in buffer system and the acid are regulated pH, medicine stability is increased, study by experiment through the inventor, all can reach the requirement of injection by the every index of the lyophilized formulations of gained of the present invention, and, lyophilized formulations stability improves, and makes medicine safer, curative effect is faster, act on stronger.
Lyophilized formulations that utilizes treatment cerebrovascular disease of the present invention provided by the invention for proof and preparation method thereof can better prepare ginsenoside Rd's lyophilized formulations, the lyophilized formulations external form that obtains is full, hardness suits, be easy to dissolving, dissolubility during redissolution is good, and the applicant has carried out a series of experiments;
Experimental example 1:
One, prescription screening
1, the selection of solution pH value:
Take by weighing an amount of ginsenoside Rd's raw material, add water and make the solution that concentration is about 200 μ g/ml, regulating pH value with 0.1mol/L hydrochloric acid or 0.5% sodium hydroxide solution respectively is 4.0,5.0,6.0,7.0,8.0,9.0,10.0; (25 ℃) are placed under room temperature, observe its appearance character in different time points, and it is an amount of to get solution simultaneously respectively, is diluted with water to concentration and is about 8 μ g/ml solution, measures its trap at 302nm wavelength place.Result of the test sees Table 1.
Table 1, injection omeprazole sodium stability of solution are investigated
| PH | Index | Time | ||||||
| 0 | 1 | 2 | 4 | 6 | 8 | 12 | ||
| 4.02 | Color | Colourless | Little Huang | Yellowish | Yellowish | → deepen gradually | ||
| Trap | 0.347 | 0.340 | 0.341 | 0.337 | - | - | - | |
| 5.06 | Color | Colourless | Little Huang | Yellowish | Yellowish | → deepen gradually | ||
| Trap | 0.349 | 0.345 | 0.339 | 0.333 | - | - | - | |
| 6.03 | Color | Colourless | Colourless | Colourless | Colourless | Colourless | Colourless | Colourless |
| Trap | 0.360 | 0.357 | 0.352 | 0.350 | 0.339 | 0.338 | 0.337 | |
| 7.09 | Color | Colourless | Colourless | Colourless | Colourless | Colourless | Colourless | Colourless |
| Trap | 0.346 | 0.347 | 0.342 | 0.351 | 0.336 | 0.332 | 0.334 | |
| 8.03 | Color | Colourless | Colourless | Colourless | Colourless | Colourless | Colourless | Colourless |
| Trap | 0.351 | 0.344 | 0.347 | 0.353 | 0.344 | 0.335 | 0.331 | |
| 9.12 | Color | Colourless | Colourless | Little Huang | Yellowish | → deepen gradually | ||
| Trap | 0.346 | 0.343 | 0.341 | 0.339 | - | - | - | |
| 10.05 | Color | Colourless | Colourless | Little Huang | Yellowish | → deepen gradually | ||
| Trap | 0.345 | 0.351 | 0.346 | 0.339 | - | - | - | |
The result shows: the pH value of solution is bigger to the stability influence of this product, and when the pH value of solution is lower than 5.0 or when being higher than 9.0, along with the prolongation of standing time, trap all has in various degree and descends, and the color of solution changes; Generally in the requirement of 4-9, the pH value scope of determining dosing is 5.5～8.5 in conjunction with the injection pH value.
2, the screening of activated carbon consumption
Select to add 0.1%, 0.2% and 0.3% activated carbon of dosing amount respectively and test, investigate ginsenoside Rd's solution of being mixed with and adding before and after the charcoal situation of change of clarity and content.
Determining of table 2, activated carbon consumption
| Before adding activated carbon | 0.1% activated carbon | 0.2% activated carbon | 0.3% activated carbon | |
| Clarity | Slight haze | Clear | Clear | Clear |
| Content (%) | 98.5％ | 97.6％ | 97.1％ | 94.8％ |
As seen from the experiment, three kinds of injection activated carbon consumptions add that the clarity of solution all makes moderate progress behind the charcoal, can both make solution reach clear and bright requirement.0.3% activated carbon consumption slightly adsorbs principal agent, the content of 0.1% and 0.2% activated carbon treatment principal agent does not have significant change, clarity and pyrogen in order to ensure solution are up to specification, and we select to add the pin activated carbon consumption of activated carbon as this product of dosing amount 0.2%.
3, the investigation of the selection of excipient and consumption thereof
Dissolubility and mouldability will be arranged preferably lyophilized formulations and than low water content, the selection of suitable filler is very important.Select for use two kinds of fillers of dextran and mannitol to test, two kinds of consumptions of every kind of screening by indexs such as the water content of dried frozen aquatic products, mouldability, dissolubility are investigated, are determined excipient kind and consumption, prescription screening sees Table 3, and prescription screening the results are shown in Table 4.
The selection of table 3, excipient and consumption
| Numbering | Prescription (mg) | |||
| The ginsenoside Rd | Mannitol | Dextran | Na2EDTA | |
| 1 | 1000 | 0 | 1500 | 75 |
| 2 | 1000 | 250 | 1250 | 75 |
| 3 | 1000 | 500 | 1000 | 100 |
| 4 | 1000 | 750 | 750 | 100 |
| 5 | 1000 | 1000 | 500 | 125 |
| 6 | 1000 | 1250 | 250 | 125 |
| 7 | 1000 | 1500 | 0 | 150 |
Table 4, excipient and dosage optimization result thereof
| The prescription numbering | Mouldability | Surface hardness | Solubility | The solubility pH value |
| 1 | Subside | Loose | Yi Rong | 7.21 |
| 2 | Not full | Loose | Yi Rong | 7.44 |
| 3 | Full, even | Hardness is suitable | Yi Rong | 7.46 |
| 4 | Full | Harder | Yi Rong | 7.51 |
| 5 | Subside, there is the crack on the surface | Loose | Yi Rong | 7.63 |
| 6 | There is the crack on not full, surface | Loose | Dissolving | 7.44 |
| 7 | There is the crack on the surface | Harder | Dissolving | 7.57 |
Experimental example 2:
One, ginsenoside-rd is to the therapeutical effect of focal cerebral ischemia in rats/reperfusion injury.
1, animal model: adopt the Longa method, intravenous injection 25% urethane 0.4ml/100g anesthetized animal keeps 37 ± 0.5 ℃ of body temperature of Mus (anus temperature) with heating lamp.Rat is lain on the back on the side's of being fixed in plate the cervical region median incision; By microsurgical technique, separate left common carotid artery and bifurcated thereof, free external carotid artery.Electricity cuts off the outer tremulous pulse of occipital artery, superior thyroid artery, pharynx that external carotid artery sends with fixed attention, and the free external carotid artery of head-end is tried one's best by far-end ligation external carotid artery with the 5-0 silk thread again.With the initial part that the vascular clamp folder closes external carotid artery, between vascular clamp and ligature, pass external carotid artery with the 5-0 silk thread and beat untwisting.Cut off external carotid artery near ligation portion, become the head end of a long 5cm drum hammer shape 3-0 filament nylon line to insert external carotid artery, the silk thread of tightening on the external carotid artery avoids hemorrhage.Remove vascular clamp, nylon wire is slowly pushed internal carotid artery, adjust direction nylon wire is injected cranial cavity, reach anterior cerebral artery when experiencing resistance.Begin to calculate from the internal carotid artery initial part, generally when 20～21mm, the middle cerebral artery section start is blocked the nylon wire insertion depth, has also blocked the side shoot blood flow from ACA, internal carotid artery and PCA simultaneously.Then untwisting is played three knot ligation again in the silk thread of external carotid artery stump, sew up the incision, nylon wire is drawn skin incisions, use when formation is poured into again extracting.When extracting nylon wire, slow in one's movements soft, feel promptly to stop withdrawing behind the resistance, shown that the head end that the nylon wire of thromboembolism expands has retreated in the stump of external carotid artery this moment, perfusion forms again.
2, test grouping: animal divides into groups with stochastic sampling.In each group experiment, ginsenoside-rd and control drug all adopt the administration of intravenous injection mode, and injection capacity is suitable.
This experiment regulation thromboembolism ischemia forms perfusion again after 1 hour, pour into after 5 hours again and observe prescription.And establish the experiment be grouped as follows:
Table 5
| Group | Size of animal | Observation index | Dosage | Inject time | ||
| Rd Mg/kg | Nimodipine μ g/kg | 1. behind the thromboembolism minute | 2. poured into again back minute | |||
| I | 1、2、3 | 50 | 10 | 10 | 5 | |
| II | 1、2、3 | 50 | 10 | 30 | 30 | |
| III | 1、2、3 | 10 | 20 | 10 | 5 | |
| IV | 1、2、3 | 2 | 40 | 10 | 5 | |
| V | 4、5 | 50 | 20 | 10 | 5 | |
3, observation index: cerebral infarct size is measured
Opening cranium and get full brain, remove olfactory bulb, cerebellum and brain stem, is at interval with 6 sections of the crown cut of brain etc. with 2.7mm.Be decided to be 1,2,3,4,5,6 from the volume end successively to the pillow end, the volume end of each section is the A face, and the pillow end is the B face.To cut into slices 2,3,4 put into 1%TTC (triphenyltetrazolium chloride, available from Sigma company, during use with dissolved in distilled water and keep in Dark Place) in, lucifuge, in 37 ℃ of water-baths dyeing 10 minutes.Normal structure includes dehydrogenase and the TTC reaction takes on a red color, and blocking tissue loses to produce to react with TTC because of dehydrogenase and is white in color.Tissue has reflected the degeneration necrosis degree of blocking cerebral tissue with the redness colour developing degree that the TTC reaction presents.The cerebral tissue infarction size is measured by automated image analysis system (model: IPAS-C, German Kontror company), and tissue degeneratiaon's degree of necrosis can show with gray scale by this analytical system, and the serious more gray scale of degree is big more.The measurement result of the average of section 2,3 measured values as each animal infarct scope adopted in this experiment.
4, to the influence of infarct size:
4.1 I organizes experimental result following (table 6.): injected first dosage in 10 minutes behind the thromboembolism, pour into second dosage of injection in back 5 minutes again.The every dosage of ginsenoside-rd is 50mg/kg, and the every dosage of nimodipine is 10 μ g/kg.
Table 6
| N | Infarct size (mm 2) | Gross area (mm 2) | Infraction is than (%) | The gray scale ratio | |
| The saline group | 10 | 21.83±12.64 | 134.66±12.94 | 16.31±8.81 | 3.11±0.71 |
| The Rd lyophilized preparation | 10 | 1.94±1.86 *** | 130.80±7.68 * | 1.44±1.33 *** | 1.63±0.50 ** |
| Nimodipine | 10 | 16.12±15.03 * | 133.08±15.14 * | 11.78±10.29 * | 2.92±0.77 * |
Compare with the saline group,
*P＞0.05,
*P＜0.05,
* *P＜0.01.
4.2 II organizes experimental result following (table 7.): injected first dosage in 30 minutes behind the thromboembolism, pour into second dosage of injection in back 30 minutes again.The every dosage of ginsenoside-rd is 50mg/kg, and the every dosage of nimodipine is 10 μ g/kg.
Table 7
| N | Infarct size (mm 2) | Gross area (mm2) | Infraction is than (%) | The gray scale ratio | |
| The saline group | 7 | 18.69±9.84 | 125.82±7.91 | 15.01±8.17 | 3.60±1.12 |
| The Rd lyophilized preparation | 10 | 3.26±2.19 *** | 132.00±7.55 * | 2.44±1.62 *** | 2.42±0.62 ** |
| Nimodipine | 9 | 10.27±9.39 * | 131.34±7.15 * | 7.58±6.58 * | 3.09±1.33 * |
Compare with the saline group,
*P＞0.05,
*P＜0.05,
* *P＜0.01.
4.3 III organizes experimental result following (table 8): injected first dosage in 10 minutes behind the thromboembolism, pour into second dosage of injection in back 5 minutes again.The every dosage of ginsenoside-rd is 10mg/kg, and the every dosage of nimodipine is 20 μ g/kg.
Table 8
| N | Infarct size (mm2) | Gross area (mm2) | Infraction is than (%) | The gray scale ratio | |
| The saline group | 1 | 20.64±11.22 | 129.16±8.69 * | 15.62±8.25 | 2.60±1.05 |
| The Rd lyophilized preparation | 1 | 5.35±3.21 *** | 129.76±8.48 * | 4.10±2.49 *** | 2.35±1.00 * |
| Nimodipine | 1 | 14.34±12.88 * | 130.24±7.89 * | 11.72±10.04 * | 2.94±1.06 * |
Compare with the saline group,
*P＞0.05,
*P＜0.05,
* *P＜0.01.
4.4 IV organizes experimental result following (table 9): injected first dosage in 10 minutes behind the thromboembolism, pour into second dosage of injection in back 5 minutes again.The every dosage of ginsenoside-rd is 2mg/kg, and the every dosage of nimodipine is 40 μ g/kg.
Table 9
| N | Infarct size (mm2) | Gross area (mm2) | Infraction is than (%) | The gray scale ratio | |
| The saline group | 9 | 21.96±13.16 | 136.31±12.83 | 16.30±3.83 | 3.03±0.85 |
| The Rd lyophilized preparation | 10 | 11.71±6.32 ** | 138.20±8.36 * | 8.45±4.57 ** | 2.89±1.89 * |
| Nimodipine | 10 | 8.45±7.45 ** | 140.00±7.60 * | 5.92±4.83 ** | 2.63±1.29 * |
Compare with the saline group,
*P＞0.05,
*P＜0.05,
* *P＜0.01.
4.5 respectively organizing experimental result gathers as following table: (table 10) ginsenoside-rd and nimodipine are to the comparison of cerebral infarction therapy effect.
Table 10
| Group | The saline group | Rd | Nimodipine | |||
| Infraction is than (%) | The gray scale ratio | Infraction is than (%) | The gray scale ratio | Infraction is than (%) | The gray scale ratio | |
| I | 16.31±8.81 | 3.11±0.71 | 1.44±1.33 *** | 1.63±0.50 ** | 11.78±10.29 * | 2.92±0.77 * |
| II | 15.01±8.17 | 3.60±1.12 | 2.44±1.62 *** | 2.42±0.62 ** | 7.58±6.58 * | 3.09±1.33 * |
| III | 15.62±8.25 | 2.60±1.05 | 4.10±2.49 *** | 2.35±1.00 ** | 11.72±10.04 * | 2.94±1.06 * |
| IV | 16.30±3.83 | 3.03±0.85 | 8.45±4.57 ** | 2.89±1.89 * | 5.92±4.83 ** | 2.63±1.29 * |
Compare with the saline group
*P＞0.05,
*P＜0.05,
* *P＜0.01.
Experimental result shows that the ginsenoside-rd of intravenous injection 2～50mg/kg can alleviate the brain tissue impairment due to the Cerebral Ischemia, mainly shows as the degree of necrosis that reduces cerebral tissue thromboembolism area, alleviates impaired cerebral tissue.Its therapeutical effect also is dose dependent, but 10～50mg/kg difference little (p＞0.05).Nimodipine treatment group shows the tendency that reduces the cerebral tissue infarct size, and its high dose group and saline group have significant difference, but total therapeutical effect is weaker than ginsenoside-rd treatment group.
5, conclusion
Experimental result shows, the ginsenoside Rd of intravenous injection 2,10 and 50mg/kg dosage all can obviously reduce the cerebral tissue necrotic area area that the perfusion of middle cerebral artery thromboembolism/again causes, its therapeutical effect is dose dependent and is better than positive control medicine nimodipine.Comprehensive above data shows, ginsenoside Rd has the obvious treatment effect to cerebral embolism/pour into the brain tissue impairment necrosis that causes again.
The specific embodiment:
Embodiment 1
1, gets ginsenoside Rd 20g, mannitol 14g, dextran 1 6g, Na2EDTA 1.5g, fully dissolve with water for injection, and be diluted to regulation volume 80%, stir, the injection active carbon of adding 0.2%, be heated to 80 ℃ and kept 10 minutes, filter carbon removal, add the injection water to nearly full dose, comprise: regulating pH value with 5% sodium hydroxide solution is 7.5, with the microporous filter membrane fine straining of 0.45 μ m, and carries out aseptic filtration with the microporous filter membrane of 0.22 μ m, the filtrate fill in the cillin bottle of 7ml, every bottled 2ml; Adorn 1000 bottles altogether, must treat lyophilizing liquid, standby;
(2) lyophilization may further comprise the steps:
1. pre-freeze: the temperature in the freeze drying box is reduced to-15 ℃～-25 ℃ respectively in advance, the lyophilizing solution for the treatment of that branch installs is put into freeze drying box and carried out pre-freeze 1～2 hour;
2. freezing: as the temperature in the freeze drying box to be reduced to-35 ℃～-45 ℃, continued freezing 3～5 hours;
3. sublimation drying: vacuum in the freeze drying box is risen to below the 1.5Kpa, close fridge, slowly heating per hour to heat up 3 ℃, was carried out sublimation drying 20～25 hours;
4. dry again: baking temperature is controlled at 25 ℃～35 ℃, until treating the freeze-dried products temperature near this temperature, freeze-day with constant temperature 4～6 hours, promptly.
Embodiment 2
1, gets ginsenoside Rd 2g, mannitol 10g, Dextran-20 g, Na2EDTA 2g, fully dissolve with water for injection, and be diluted to regulation volume 80%, stir, the injection active carbon of adding 0.1%, be heated to 80 ℃ and kept 10 minutes, filter carbon removal, add the injection water to nearly full dose, comprise: regulating pH value with 2% sodium hydroxide solution is 7.5, with the microporous filter membrane fine straining of 0.45 μ m, and carries out aseptic filtration with the microporous filter membrane of 0.22 μ m, the filtrate fill in the cillin bottle of 7ml, every bottled 2ml; Adorn 1000 bottles altogether, must treat lyophilizing liquid, standby;
(2) lyophilization may further comprise the steps:
1. pre-freeze: the temperature in the freeze drying box is reduced to-15 ℃～-25 ℃ respectively in advance, the lyophilizing solution for the treatment of that branch installs is put into freeze drying box and carried out pre-freeze 1～2 hour;
2. freezing: as the temperature in the freeze drying box to be reduced to-35 ℃～-45 ℃, continued freezing 3～5 hours;
3. sublimation drying: vacuum in the freeze drying box is risen to below the 1.5Kpa, close fridge, slowly heating per hour to heat up 3 ℃, was carried out sublimation drying 20～25 hours;
4. dry again: baking temperature is controlled at 25 ℃～35 ℃, until treating the freeze-dried products temperature near this temperature, freeze-day with constant temperature 4～6 hours, promptly.
Embodiment 3
1, gets ginsenoside Rd 100g, mannitol 70g, dextran 80g, Na2EDTA 7.5g, fully dissolve with water for injection, and be diluted to regulation volume 80%, stir, the injection active carbon of adding 0.2%, be heated to 80 ℃ and kept 10 minutes, filter carbon removal, add the injection water to nearly full dose, comprise: regulating pH value with 10% sodium hydroxide solution is 7.5, with the microporous filter membrane fine straining of 0.45 μ m, and carries out aseptic filtration with the microporous filter membrane of 0.22 μ m, the filtrate fill in the cillin bottle of 10ml, every bottled 2ml; Adorn 1000 bottles altogether, must treat lyophilizing liquid, standby;
(2) lyophilization may further comprise the steps:
1. pre-freeze: the temperature in the freeze drying box is reduced to-15 ℃～-25 ℃ respectively in advance, the lyophilizing solution for the treatment of that branch installs is put into freeze drying box and carried out pre-freeze 1～2 hour;
2. freezing: as the temperature in the freeze drying box to be reduced to-35 ℃～-45 ℃, continued freezing 3～5 hours;
3. sublimation drying: vacuum in the freeze drying box is risen to below the 1.5Kpa, close fridge, slowly heating per hour to heat up 3 ℃, was carried out sublimation drying 20～25 hours;
4. dry again: baking temperature is controlled at 25 ℃～35 ℃, until treating the freeze-dried products temperature near this temperature, freeze-day with constant temperature 4～6 hours, promptly.
Claims (9)
1, a kind of lyophilized formulations for the treatment of cerebrovascular disease is made after lyophilization by the solution that contains ginsenoside Rd and pharmaceutically acceptable excipient.
2, the lyophilized formulations of treatment cerebrovascular disease according to claim 1, described ginsenoside Rd is a kind of or any one the above mixture that is selected from ginsenoside-rd, ginsenoside-rd hydrate or their derivant or their salt.
3, the lyophilized formulations of treatment cerebrovascular disease according to claim 1, described pharmaceutically acceptable excipient are one or more the materials that is selected from mannitol, dextran, lactose, sodium chloride, glucose, Na2EDTA, glycine or other the pharmaceutically acceptable excipient.
4, the lyophilized formulations of treatment cerebrovascular disease according to claim 3, described pharmaceutically acceptable excipient is to be selected from mannitol, dextran, Na2EDTA.
5, the lyophilized formulations of treatment cerebrovascular disease according to claim 1, the pH value of solution that it is characterized in that described ginsenoside Rd of containing and pharmaceutically acceptable excipient is 5.5～8.5.
6, the lyophilized formulations of treatment cerebrovascular disease according to claim 1 is characterized in that described solution also can contain one or more materials in alkali compounds, buffer system and the acid of the described solution pH value of pharmaceutically acceptable scalable.
7, the lyophilized formulations of treatment cerebrovascular disease according to claim 1, it is characterized in that described solution, also contain acceptable adjuvant on the conventional pharmaceutical that comprises stabilizing agent, analgesics and buffer agent and one or more material in the medicine with other miscellaneous functions is arranged.
8, according to the lyophilized formulations of the described treatment cerebrovascular disease of claim 1～7, it is characterized in that: after lyophilization, make by the solution that contains ginsenoside Rd and excipient; The pH value of described solution is 5.5～8.5; Described solution volume ratio by weight contains ginsenoside Rd 0.01%～10%, described solution volume ratio by weight contains excipient 0.5%～40%, wherein, the proportion of composing of excipient is: mannitol: dextran: Na2EDTA is 30～65%: 55～27.5%: 15～7.5%, and the surplus of described solution is a solvent; Described solution is solvent with water and/or pharmaceutically acceptable organic solvent.
9, a kind of preparation method for the treatment of the lyophilized formulations of cerebrovascular disease comprises:
(1) preparation contains the solution of ginsenoside Rd, pharmaceutically acceptable excipient, removes impurity, pyrogen, decolouring, and the method for filtration sterilization comprises: the pH value of regulator solution is 5.5～8.5; In the described solution ginsenoside Rd's content by weight volume ratio be 0.01%～10% and excipient content by weight volume ratio be 0.5%～40%; Described pharmaceutically acceptable excipient is the mixture of mannitol, dextran, Na2EDTA, and proportion of composing is 30～65%: 55～27.5%: 15～7.5%; Described remove pyrogen be with solution by adding 0.05%～5% active carbon, preferred 0.1%～2%, under 25 ℃～60 ℃, preferred 20 ℃～30 ℃, stirred 10～30 minutes, filtering decarbonization is finished;
(2) described lyophilization may further comprise the steps:
1. pre-freeze: the temperature in the freeze drying box is reduced to-15 ℃～-25 ℃ respectively in advance, the lyophilizing solution for the treatment of that branch installs is put into freeze drying box and carried out pre-freeze 1～2 hour;
2. freezing: as the temperature in the freeze drying box to be reduced to-35 ℃～-45 ℃, continued freezing 3～5 hours;
3. sublimation drying: vacuum in the freeze drying box is risen to below the 1.5Kpa, close fridge, slowly heating per hour to heat up 3 ℃, was carried out sublimation drying 20～25 hours;
4. dry again: as baking temperature to be controlled at 25 ℃～35 ℃, until treating the freeze-dried products temperature near this temperature, freeze-day with constant temperature 4～6 hours.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100512325A CN100506235C (en) | 2006-09-26 | 2006-09-26 | Freeze-dried preparation for treating cerebral vascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100512325A CN100506235C (en) | 2006-09-26 | 2006-09-26 | Freeze-dried preparation for treating cerebral vascular disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1943583A true CN1943583A (en) | 2007-04-11 |
| CN100506235C CN100506235C (en) | 2009-07-01 |
Family
ID=38043377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100512325A Expired - Fee Related CN100506235C (en) | 2006-09-26 | 2006-09-26 | Freeze-dried preparation for treating cerebral vascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100506235C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110025623A (en) * | 2019-03-21 | 2019-07-19 | 李和伟 | A kind of lyophilized preparation and its preparation method and application |
-
2006
- 2006-09-26 CN CNB2006100512325A patent/CN100506235C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110025623A (en) * | 2019-03-21 | 2019-07-19 | 李和伟 | A kind of lyophilized preparation and its preparation method and application |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100506235C (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1308012C (en) | Chinese medicine composition for treating cerebral hemorrhage and its prepn | |
| CN1704085A (en) | Pharmaceutical composition with immunoregulation function and method for preparing the same | |
| CN110538189A (en) | Eucommia ulmoides extract composition for treating renal fibrosis and application thereof | |
| CN1762401A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases, preparation method and application thereof | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN114869928B (en) | Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof | |
| CN100506235C (en) | Freeze-dried preparation for treating cerebral vascular disease | |
| US12115204B2 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
| CN1823875A (en) | Medicinal composition of trichosanthes rind and its preparation method | |
| CN1733070A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN111346089A (en) | Medicinal preparation and preparation method thereof | |
| CN102048824B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease and application thereof | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN1762362A (en) | Medicinal composition with red sage root component for treating cardiovascular and cerebrovascular disease and its application | |
| CN1733013A (en) | Novel route for administering hairy holly injection and preparation process thereof | |
| CN1698802A (en) | Chinese medicinal compound preparation for treating vascular diseases and its preparing process | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1927214A (en) | Injection for treating cerebrovascular disease and its preparing process | |
| CN110478384B (en) | Method for extracting total coumarins from radix Saposhnikoviae, and its application in preparing composition for enhancing drug effect of central nervous system | |
| CN109793745B (en) | Application of aspirin in preparation of medicine for treating dyskinesia and pharmaceutical composition thereof | |
| CN107998117B (en) | A kind of combination of oral medication for treating capillary leak syndrome | |
| CN1813836A (en) | Medicinal composition for treating cardio-cerebrovascular disease | |
| CN1593574A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Qian Youbin Document name: Notice of termination |
|
| DD01 | Delivery of document by public notice |
Addressee: Qian Youbin Document name: Notification of Termination of Procedure |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 550018 6th Floor, Kekaiyuan, Koujie Road Estuary, Wudang District, Guiyang City, Guizhou Province Patentee after: Xinbang Pharmacy Co., Ltd., Guizhou Address before: 550014 Xinbang Avenue 227, Baiyun Economic Development Zone, Guiyang City, Guizhou Province Patentee before: Xinbang Yuandong Pharmaceutical Co., Ltd., Guizhou |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090701 Termination date: 20190926 |